강직성 척추염 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Ankylosing Spondylitis Market size is expected to reach USD 12.71 Billion in 2034 from USD 7.11 Billion (2025) growing at a CAGR of 6.66% during 2026-2034.

The Global Ankylosing Spondylitis Market is experiencing steady expansion driven by rising diagnosis rates and increasing awareness of inflammatory autoimmune disorders. Improved imaging technologies and earlier screening protocols are enabling timely identification of ankylosing spondylitis, particularly among younger populations. The growing burden of chronic back pain and genetic predisposition factors are further contributing to demand for targeted biologics and advanced therapeutic interventions across developed and emerging healthcare systems.

Key growth drivers include the strong adoption of biologic therapies such as TNF inhibitors and IL-17 inhibitors, alongside expanding reimbursement coverage in developed economies. Pharmaceutical companies are investing heavily in research and development to introduce next-generation biologics with improved efficacy and safety profiles. Additionally, patient advocacy initiatives and educational campaigns are improving disease awareness, thereby accelerating treatment uptake and expanding the addressable patient pool.

Looking ahead, the market is poised for robust growth fueled by biosimilar launches, precision medicine approaches, and advancements in immunology research. Emerging markets are expected to contribute significantly due to improving healthcare infrastructure and rising healthcare expenditure. Digital health integration for remote monitoring and adherence tracking will further enhance patient outcomes, positioning the ankylosing spondylitis market for sustained long-term expansion.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug Class

• Non-Steroidal Anti-Inflammatory Drug (NSAID)
• TNF Inhibitors
• Other Drug Classes

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Others

COMPANIES PROFILED

• AbbVie Inc, Amgen Inc, Pfizer Inc, UCB Inc, Novartis AG, Eli Lilly and Company, Johnson and Johnson Services Inc, Merck and Co Inc, Izana Biosciences, Zydus Lifescience Ltd
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ANKYLOSING SPONDYLITIS MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug Class
• 4.2. Non-Steroidal Anti-Inflammatory Drug (NSAID) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. TNF Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Other Drug Classes Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ANKYLOSING SPONDYLITIS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Distribution Channel
• 5.2. Hospital Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Retail Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ANKYLOSING SPONDYLITIS MARKET: BY REGION 2022-2034(USD MN)

• 6.1. Regional Outlook
• 6.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.2.1 By Drug Class
  • 6.2.2 By Distribution Channel
  • 6.2.3 United States
  • 6.2.4 Canada
  • 6.2.5 Mexico
• 6.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.3.1 By Drug Class
  • 6.3.2 By Distribution Channel
  • 6.3.3 United Kingdom
  • 6.3.4 France
  • 6.3.5 Germany
  • 6.3.6 Italy
  • 6.3.7 Russia
  • 6.3.8 Rest Of Europe
• 6.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.4.1 By Drug Class
  • 6.4.2 By Distribution Channel
  • 6.4.3 India
  • 6.4.4 Japan
  • 6.4.5 South Korea
  • 6.4.6 Australia
  • 6.4.7 South East Asia
  • 6.4.8 Rest Of Asia Pacific
• 6.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.5.1 By Drug Class
  • 6.5.2 By Distribution Channel
  • 6.5.3 Brazil
  • 6.5.4 Argentina
  • 6.5.5 Peru
  • 6.5.6 Chile
  • 6.5.7 South East Asia
  • 6.5.8 Rest of Latin America
• 6.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 6.6.1 By Drug Class
  • 6.6.2 By Distribution Channel
  • 6.6.3 Saudi Arabia
  • 6.6.4 UAE
  • 6.6.5 Israel
  • 6.6.6 South Africa
  • 6.6.7 Rest of the Middle East And Africa

Chapter 7. COMPETITIVE LANDSCAPE

• 7.1. Recent Developments
• 7.2. Company Categorization
• 7.3. Supply Chain & Channel Partners (based on availability)
• 7.4. Market Share & Positioning Analysis (based on availability)
• 7.5. Vendor Landscape (based on availability)
• 7.6. Strategy Mapping

Chapter 8. COMPANY PROFILES OF GLOBAL ANKYLOSING SPONDYLITIS INDUSTRY

• 8.1. Top Companies Market Share Analysis
• 8.2. Company Profiles
  • 8.2.1 AbbVie Inc
  • 8.2.2 Amgen Inc
  • 8.2.3 Pfizer Inc
  • 8.2.4 UCB Inc
  • 8.2.5 Novartis AG
  • 8.2.6 Eli Lilly And Company
  • 8.2.7 Johnson And Johnson Services Inc
  • 8.2.8 Merck And Co. Inc
  • 8.2.9 Izana Biosciences
  • 8.2.10 Zydus Lifescience Ltd